Clinical Trial Update: Myeloablative Conditioning Orca-T & Allogeneic Donor-Derived CD19/CD22-CAR TCells in B-Cell ALL [Phase 1]

View source ↗

Summary

This clinical trial update covers a Phase 1 study evaluating myeloablative conditioning with Orca-T plus donor-derived CD19/CD22-CAR T cells for B-cell acute ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia

Drugs mentioned

• Allogeneic donor-derived CD19/CD22-CAR T cells (CD19/CD22-CAR T cells)
• Orca-T

Snippet

Sponsor: Stanford University | Conditions: Lymphoid Leukemia | Phase 1 | Status: ACTIVE_NOT_RECRUITING